AZN AstraZeneca
- 78.020
- +1.250+1.63%
- 77.840
- -0.180-0.23%
AstraZeneca News
Tempus Announces Expansion of Collaboration With AstraZeneca to Leverage Tempus Next to Support Guideline-directed Biomarker Testing in NSCLC
Tempus, a leader in artificial intelligence and precision medicine, today announces an expansion of its collaboration with AstraZeneca, which leverages Tempus Next to arm physicians with technology that supports the
Ontario Court Approves AstraZeneca/Fusion Acquisition Plan
J&J Says Rybrevant Combo Bests AstraZeneca's Tagrisso in Type of Lung Cancer
Express News | Fusion Pharmaceuticals Obtains Final Court Approval For Acquisition By AstraZeneca Subsidiary; Shareholders To Receive $21/Share Plus $3 Contingent Value Right
Fusion Pharmaceuticals Shareholders to Get Deferred Payment in Form of Contingent Value Right of $3/Shr If Milestone Is Achieved >FUSN
Fusion Pharmaceuticals Shareholders to Get Deferred Payment in Form of Contingent Value Right of $3/Shr If Milestone Is Achieved >FUSN
Fusion Pharmaceuticals Shareholders to Receive $21/Shr in Cash Upfront on Completion of Deal >FUSN
Fusion Pharmaceuticals Shareholders to Receive $21/Shr in Cash Upfront on Completion of Deal >FUSN
Express News | Fusion Pharmaceuticals Inc - Pursuant to Plan, a Wholly-Owned Subsidiary of AstraZeneca Will Acquire All Issued and Outstanding Shares of Fusion
Fusion Pharmaceuticals Receives Final Court Order Approving AstraZeneca Deal >FUSN
Fusion Pharmaceuticals Receives Final Court Order Approving AstraZeneca Deal >FUSN
The Most Profitable Biotechnology Company in the World
Pfizer (PFE) Up 1.8% Since Last Earnings Report: Can It Continue?
Express News | AstraZeneca CEO Says No Need For Further Mergers And Acquisitions; Inflation Reduction Act Could Impact Top Line By $500M; Pascal Soriot Aims To Nearly Double Sales By 2030, No Plans To Retire
AstraZeneca CEO: Company Doesn't Need Further Mergers and Acquisitions
AstraZeneca CEO: Company Doesn't Need Further Mergers and Acquisitions
AstraZeneca's CEO Pascal Soriot Says He Has No Plans to Retire
AstraZeneca's CEO Pascal Soriot Says He Has No Plans to Retire
AstraZeneca CEO: U.S. Inflation Reduction Act Could Hit Top Line By Around $500M
AstraZeneca CEO: U.S. Inflation Reduction Act Could Hit Top Line By Around $500M
Positive Outlook for Cellectis SA With Strategic AstraZeneca Partnership and Promising Clinical Developments
AstraZeneca Is Maintained at Buy by Argus Research
AstraZeneca Is Maintained at Buy by Argus Research
Express News | Argus Research Maintains Buy on AstraZeneca, Raises Price Target to $85
Third Human Bird Flu Case Found in U.S.
AstraZeneca, Novo Nordisk, Novartis Show Innovation Momentum -- Market Talk
1551 GMT - AstraZeneca, Novo Nordisk and Novartis are charting strong innovation narrative that should boost near and mid-term earnings momentum, Goldman Sachs analysts say in a note. AstraZeneca's in
Goldman Sachs Raises Obesity Drug Market Estimate to $130B
Analysis
Price Target
No Data
